Senicapoc
- Generic Name
- Senicapoc
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15F2NO
- CAS Number
- 289656-45-7
- Unique Ingredient Identifier
- TS6G201A6Q
- Background
Senicapoc (ICA-17043) is a novel Gardos channel blocker. It is being investigated for the treatment of sickle cell disease.
- Indication
Investigated for use/treatment in anemia (sickle cell) and asthma.
- Associated Conditions
- -
- Associated Therapies
- -
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT06714123
- Locations
- π©π°
Aarhus University Hospital, Aarhus N, Denmark
π©π°Gentofte Hospital, Hellerup, Denmark
π©π°Odense University Hospital, Odense C, Denmark
Senicapoc in Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 55
- Registration Number
- NCT04804241
- Locations
- πΊπΈ
University of California, Davis Alzheimer's Disease Center, Sacramento, California, United States
πΊπΈUC Davis Alzheimer's Disease Center East Bay, Walnut Creek, California, United States
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 46
- Registration Number
- NCT04594668
- Locations
- π©π°
Odense University Hospital, Odense, Denmark
π©π°Hvidovre Hospital, Hvidovre, Denmark
π©π°Aalborg University Hospital, Aalborg, Denmark
Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Icagen
- Target Recruit Count
- 69
- Registration Number
- NCT00861185
Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Icagen
- Target Recruit Count
- 34
- Registration Number
- NCT00861211
- Locations
- π¬π§
Guy's Drug Research Unit, London, UK, United Kingdom
π¬π§Medicines Evaluation Unit, Manchester, UK, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.